Deep Vein Thrombosis Self Care
Links shared publicly online about this topic
XARELTO achieves net clinical benefit in treatment of patients with DVT
news-medical.net — “Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.” View full resource at news-medical.net
Most Recently Shared on September 2, 2010 at 11:47 am By:
Stroke News: XARELTO achieves net clinical benefit in treatment of patients with DVT: Bayer HealthCare Pharmaceu... http://twurl.nl/zafvpq
UT Medical Center - March is Deep Vein Thrombosis Awareness Month
utmedicalcenter.org — “University of Tennessee Medical Center has a rich history in the community of providing patient-centered care and remaining at the forefront of research, technology and treatments.” View full resource at utmedicalcenter.org
Most Recently Shared on March 23, 2009 at 6:36 pm By:
March is Deep Vein Thrombosis Awareness Month http://tinyurl.com/czshm5
Pulse - Mobile phone study, the DVT self-test and meet Harry the heavyweight baby
pulsetoday.co.uk — “Pulse - Mobile phone study, the DVT self-test and meet Harry the heavyweight baby” View full resource at pulsetoday.co.uk
Most Recently Shared on April 23, 2010 at 9:57 am By:
PulseToday Health News and Medical Publisher
Mobile phone study, the DVT self-test and meet harry the heavyweight baby: Our roundup of news headlines on Friday... http://bit.ly/bILZZt
Medical News: No DVT Advantage for Dalteparin - in Critical Care, General Critical Care from MedPage Today
medpagetoday.com — “Use of the low molecular weight heparin dalteparin was not found to be superior to unfractionated heparin for preventing deep vein thrombosis in critically ill patients, according to a multicenter stu” View full resource at medpagetoday.com
Most Recently Shared on March 24, 2011 at 10:00 am By:
Hisham Rana, MD Doctor and Physician
Study: No DVT advantage for dalteparin (NEJM) http://bit.ly/hpzUAB - #health
Medical News: No DVT Advantage for Dalteparin - in Critical Care, General Critical Care from MedPage Today
medpagetoday.com — “Use of the low molecular weight heparin dalteparin was not found to be superior to unfractionated heparin for preventing deep vein thrombosis in critically ill patients, according to a multicenter stu” View full resource at medpagetoday.com
Most Recently Shared on March 23, 2011 at 7:32 pm By:
No DVT Advantage for Dalteparin (CME/CE): (MedPage Today) -- Use of the low molecular weight… http://goo.gl/fb/rdsZv
Clinical Decision Rules May Safely Rule Out Deep Vein Thrombosis - QualityPoint Technologies
qualitypointtech.net — “Suspected DVT can safely be ruled out using either of 2 decision rules plus a point-of-care D-dimer test, reducing unnecessary referrals for compression ultrasonography. Medscape Medical News” View full resource at qualitypointtech.net
Most Recently Shared on January 20, 2011 at 6:01 pm By:
Clinical Decision Rules May Safely Rule Out Deep Vein Thrombosis: Suspected DVT can safely be ruled out using eith... http://bit.ly/gkfg6Q
Bayer HealthCare - FDA Approves Xarelto® (rivaroxaban tablets) for the Prophylaxis of Deep Vein Thrombosis Which May Lead to a Pulmonary Embolism in Patients Undergoing Knee or Hip Replacement Surgery
press.bayerhealthcare.com — “Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. The company combines the global activities of the divisions Animal Health, Bayer Schering Pharma, Consumer Care and Diabetes Care. More than 50,000 people are employed by Bayer HealthCare worldwide. Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality ” View full resource at press.bayerhealthcare.com
Most Recently Shared on July 3, 2011 at 6:25 pm By:
FDA Approves Xarelto® for the Prophylaxis of Deep Vein Thrombosis ......... http://t.co/yn1AQsl
Quality Care For Stroke Patients: UH Case Medical Center Receives Get With The Guidelines Gold Plus Performance Achievement Award
medicalnewstoday.com — “For the second consecutive year University Hospitals (UH) Case Medical Center has received the American Heart Association/American Stroke Association's Get With The Guidelines® Stroke Gold Plu” View full resource at medicalnewstoday.com
Most Recently Shared on October 22, 2010 at 12:34 pm By:
Quality Care For Stroke Patients: UH Case Medical Center Receives Get With The Guidelines Gold Plus Performance Achi... http://ow.ly/19A3gb
Antipsychotic drugs and risk of venous thromboembolism: nested case-control study -- Parker et al. 341 -- bmj.com
bmj.com — “Parker, Chris; Coupland, Carol; Hippisley-Cox, Julia” View full resource at bmj.com
Most Recently Shared on September 22, 2010 at 2:23 pm By:
Ohio Family Practice Physician Group
Small increased risk -- but questionable clinical significance -- of DVT with antipsychotics http://bit.ly/aGaETc
How to Prepare for Surgery - CarePages.com
cms.carepages.com — “Proper care can help reduce complications during and after surgery, including the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE).” View full resource at cms.carepages.com
Most Recently Shared on December 16, 2009 at 7:48 pm By:
Interesting piece on how to prepare for surgery from our partner site, CarePages. http://tinyurl.com/yjofkhz
Medical Research Varies On Risks Of Popular Birth Control Pills Yaz, Yasmin
medicalnewstoday.com — “As of mid-February, Bayer HealthCare faced more than 1,100 lawsuits in the U.S. from women alleging that the synthetic progestin in the birth control pills Yasmin and Yaz causes serious health pro” View full resource at medicalnewstoday.com
Most Recently Shared on April 21, 2010 at 5:15 pm By:
Medical Research Varies On Risks Of Popular Birth Control Pills Yaz, Yasmin http://mnt.to/3BxS #sexualhealth
Positive Results From Chronic Study With Bayer's Rivaroxaban Will Be Presented As A Late Breaker At ASH 2009
medicalnewstoday.com — “Findings from the phase iii einstein-extension study will be presented in the late breaking abstract session on december 8, 2009, (7:30 am est, hall f, ernest n. morial convention center) at the 5” View full resource at medicalnewstoday.com
Most Recently Shared on November 21, 2009 at 1:11 pm By:
MNT Cardiovascular Health News
Positive Results From Chronic Study With Bayer's Rivaroxaban Will Be Presented As A Late Breaker At ASH 2009: F.. http://bit.ly/5wpLCD
New Blood Thinner May Help Fight Dangerous Leg Clots Information on Healthline
healthline.com — “Read about anticoagulants, and other breaking health care stories in the Health Day News section of Healthline.” View full resource at healthline.com
Most Recently Shared on December 5, 2010 at 9:24 am By:
#hbp New Blood Thinner May Help Fight Dangerous Leg Clots http://sns.ly/ygM74 #blood
FDA approves new anti-clotting drug for use after hip and knee replacements - McKnight's Long Term Care News
mcknights.com — “The Food and Drug Administration has approved a new oral anticoagulant that helps prevent deep vein thrombosis in people recovering from knee or hip replacements.” View full resource at mcknights.com
Most Recently Shared on July 6, 2011 at 12:39 pm By:
McKnight's LTC News Health News and Medical Publisher
FDA approves new anti-clotting drug for use after hip and knee replacements http://bit.ly/pIRzaY #healthcare
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
News-Medical.Net
Stay up to date with the latest Stroke news and research via News-Medical.Net
-
utmedicalcenter
Official Twitter of UT Medical Center: preventive medicine, health, cooking/eating healthy, cutting-edge treatments, maintaining a healthy lifestyle
-
PulseToday
PulseToday.co.uk - Medical news, views, education and clinical information to GPs, nurses and other health professionals.
Advertisement
